Abstract

The present invention belongs to the field of biomedicine. Specifically, the present invention relates to an improved T-cell therapy. More specifically, the present invention relates to enhancing the cancer treatment efficacy of therapeutic T cells (such as CAR-T or TCR-T cells) through stimulation with living cells expressing cancer-related antigens.

No Suitable Figure